In addition, treatment with either EZH2 siRNA or tyrosine kinase inhibitor (TKI) alone increased expression of H3K27me3 targets, and combined treatment enhanced these effects and decreased the proportion of CSCs in CML compared to treatment with TKI alone [42]. The gene discussed is EZH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.